SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the appointment of Christine M. Gorjanc to its Board of Directors, effective immediately.
Christine currently serves as chief financial officer at NETGEAR, Inc. (NASDAQ: NTGR), a global networking company that delivers innovative products to consumers, businesses, and service providers. Prior to joining NETGEAR as vice president of finance in November 2005, Ms. Gorjanc served as vice president, controller, treasurer, and assistant secretary for Aspect Communications Corporation, a provider of workforce and customer management solutions from September 1996 through November 2005. From October 1988 through September 1996, she served as the manager of tax for Tandem Computers, Inc., a provider of fault-tolerant computer systems. From June 1987 through October 1988, Ms. Gorjanc served as the manager of tax operations for Xidex Corporation, a manufacturer of storage devices. Prior to that, Ms. Gorjanc worked in public accounting for eight years with a number of accounting firms.
“We are thrilled to have Christine joining our board of directors,” said Randy Scott, chairman and CEO of Invitae. “Christine’s experience as an executive and finance leader with a rapidly growing international technology company operating in highly competitive markets will benefit Invitae as we advance towards our goal of improving healthcare for billions of people.”
“I have always had a deep interest in personalized medicine and admire Invitae’s mission to empower patients, improve healthcare, and bring genetics into mainstream medicine,” said Ms. Gorjanc. “Invitae’s commitment to make genetic testing more affordable and accessible will advance the quality of medical care for patients and their families.”
Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a single diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics and other rare disease areas.